PE-22-28

PE-22-28 is a research peptide that the supplied guide associates with inflammatory signaling and immune responses. The guide's account of its biological origin and mechanism requires independent verification and should not be treated as evidence of therapeutic benefit.

The interleukin-1 receptor antagonist is an endogenous protein that limits signaling through the interleukin-1 receptor system. The guide attributes PE-22-28 to this protein, but the supplied material does not establish that relationship or demonstrate that the peptide shares its biological activity.

The guide proposes that PE-22-28 suppresses interleukin-1 signaling and thereby influences inflammatory and immune processes. It supplies no experimental methods or supporting references that establish target engagement, selectivity, or downstream effects for this particular peptide.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 01 · Basic biology

A biological mechanism or molecular interaction is described. No claim about human outcomes.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents PE-22-28 as potentially relevant to persistent inflammatory disorders and autoimmune disease. It also suggests possible relevance to joint discomfort, inflammation in the nervous system, and cognition. These are claims made by the guide, rather than demonstrated outcomes supported by the supplied material.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The peptide's stated origin and interleukin-1 mechanism remain unverified and may reflect a compound-identification error. The notes do not establish the availability or quality of compound-specific preclinical or human evidence.

Safety data are limited, and the guide's favorable tolerability characterization is not supported by documented studies in the supplied material. Its mention of digestive symptoms does not establish their frequency or causal relationship to PE-22-28, and longer-term risks remain unclear. This information is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “PE-22-28 inflammation modulation”
• “PE-22-28 autoimmune disorder treatment”
• “PE-22-28 peptide clinical studies”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN